KLK3 and Familial prostate cancer: Moreover, the lack of biomarkers for aggressive disease, combined with opportunistic PSA screening, has led to large scale overdiagnosis and overtreatment of clinically insignificant prostate cancers, thus new biomarkers are urgently needed.